Free Trial

Bank Pictet & Cie Europe AG Sells 5,339 Shares of Zoetis Inc. $ZTS

Zoetis logo with Medical background

Key Points

  • Bank Pictet & Cie Europe AG reduced its stake in Zoetis Inc. by 1.3%, now holding 392,560 shares after selling 5,339 shares in the second quarter.
  • Zoetis Inc. reported earnings of $1.76 per share, exceeding estimates by $0.14, with revenue of $2.46 billion, representing a year-over-year increase of 4.2%.
  • Five analysts rated Zoetis with a "Buy," while four assigned a "Hold," reflecting a consensus rating of "Moderate Buy" with an average target price of $200.88.
  • Interested in Zoetis? Here are five stocks we like better.

Bank Pictet & Cie Europe AG cut its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 1.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 392,560 shares of the company's stock after selling 5,339 shares during the period. Zoetis makes up 1.3% of Bank Pictet & Cie Europe AG's investment portfolio, making the stock its 20th biggest holding. Bank Pictet & Cie Europe AG owned 0.09% of Zoetis worth $61,220,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Vanguard Group Inc. boosted its holdings in Zoetis by 0.5% in the first quarter. Vanguard Group Inc. now owns 41,556,164 shares of the company's stock worth $6,842,222,000 after purchasing an additional 189,287 shares in the last quarter. Polen Capital Management LLC boosted its holdings in Zoetis by 17.6% in the first quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company's stock worth $1,448,401,000 after purchasing an additional 1,313,653 shares in the last quarter. Northern Trust Corp boosted its holdings in Zoetis by 1.2% in the first quarter. Northern Trust Corp now owns 6,504,902 shares of the company's stock worth $1,071,032,000 after purchasing an additional 78,508 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in Zoetis by 2.2% in the first quarter. Goldman Sachs Group Inc. now owns 5,146,024 shares of the company's stock worth $847,293,000 after purchasing an additional 109,791 shares in the last quarter. Finally, Brown Advisory Inc. boosted its holdings in Zoetis by 7.6% in the first quarter. Brown Advisory Inc. now owns 4,408,542 shares of the company's stock worth $725,866,000 after purchasing an additional 312,746 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Zoetis Stock Down 0.5%

NYSE ZTS opened at $141.03 on Friday. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. The firm has a 50-day simple moving average of $150.45 and a 200 day simple moving average of $155.86. Zoetis Inc. has a twelve month low of $139.34 and a twelve month high of $197.51. The stock has a market cap of $62.50 billion, a PE ratio of 24.27, a PEG ratio of 2.27 and a beta of 0.89.

Zoetis (NYSE:ZTS - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business had revenue of $2.46 billion during the quarter, compared to analysts' expectations of $2.41 billion. During the same quarter last year, the company earned $1.56 earnings per share. The firm's revenue was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on ZTS. Leerink Partners cut shares of Zoetis from an "outperform" rating to a "market perform" rating and decreased their price target for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Argus reaffirmed a "buy" rating and issued a $190.00 price target on shares of Zoetis in a research report on Tuesday, September 9th. Piper Sandler raised their price target on Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a research report on Monday, August 11th. Leerink Partnrs downgraded Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 17th. Finally, Stifel Nicolaus downgraded Zoetis from a "buy" rating to a "hold" rating and lowered their price target for the company from $165.00 to $160.00 in a research report on Wednesday, June 18th. Five analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $200.88.

View Our Latest Stock Analysis on ZTS

About Zoetis

(Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Read More

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Zoetis Right Now?

Before you consider Zoetis, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zoetis wasn't on the list.

While Zoetis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report
Like this article? Share it with a colleague.